*1.Full Name(Required.)

*2.Title(Required.)

*3.Email(Required.)

*4.Address (Street Address, City, State, Zip Code)(Required.)

*5.Missouri Pharmacist License Number(Required.)

*6.What is microdosing?(Required.)

a. Taking a full dose of medication to achieve maximum therapeutic effect

b. Taking very small amounts of a medication to achieve maximum therapeutic effect

c. Administering medication through a micro-needle

d. Taking multiple small doses of different medications simultaneously

*7.Microdosing is often used in which of the following scenarios?(Required.)

a. Acute management of opioid overdose

b. Management of opioid dependence to minimize withdrawal symptoms and cravings

c. Immediate relief of severe pain

d. Treatment of bacterial infections

*8.When initiating buprenorphine microdosing, what is a key advantage regarding the patient's opioid withdrawal status?(Required.)

a. The patient must be in severe opioid withdrawal to begin treatment

b. The patient must have completely stopped opioid use for at least 48 hours

c. The patient must be in mild opioid withdrawal to start microdosing

d. The patient does not have to be in active opioid withdrawal to initiate treatment

*9.Which of the following describes the Azar method, an alternative technique for transitioning from methadone to buprenorphine/naloxone?(Required.)

a. Gradual tapering of methadone followed by immediate administration of buprenorphine/naloxone

b. Overlapping the use of a fentanyl patch with buprenorphine/naloxone sublingual tablets

c. Direct substitution of methadone with buprenorphine/naloxone at equivalent doses

d. Using buprenorphine/naloxone only after a 72-hour methadone washout period

*10.What is the initial dosing regimen for Low-Dose Opioid Induction (LDOI) with buprenorphine/naloxone sublingual (SL) tablets?(Required.)

a. 2/0.5 mg repeated hourly

b. 4/1 mg twice daily

c. 0.5/0.125 mg (1/4 of a 2/0.5 mg tablet) twice daily

d. 8/2 mg once daily

*11.What is the total recommended daily dose of buprenorphine for macrodosing?(Required.)

a. 24 mg

b. 96 mg

c. 64 mg

d. 32 mg

*12.Which of the following is NOT a benefit of buprenorphine macrodosing?(Required.)

a, Achieve a full therapeutic dose rapidly

b. Avoid withdrawal symptoms completely

c. Reduce delays in hospital discharge and transition to outpatient treatment

d. Induction can be achieved pre-hospital, in the emergency department, or inpatient

*13.What unique properties allow for macrodosing for the treatment of opioid withdrawal?(Required.)

a. Low affinity for mu-opioid receptor (MOR), fast dissociation, and no ceiling effect

b. High affinity for mu-opioid receptor (MOR), fast dissociation, and ceiling effect

c. High affinity for mu-opioid receptor (MOR), slow dissociation, and ceiling effect

d. Low affinity for mu-opioid receptor (MOR), slow dissociation, and ceiling effect

*14.Studies have demonstrated macrodosing induction in the following settings EXCEPT for:(Required.)

a. Emergency department

b. General medicine unit

c. Ambulance

d. Outpatient addiction treatment center

*15.True or False: The patient is required to receive naloxone prior to initiating macrodosing.(Required.)

True

False